At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
KURA Kura Oncology
Pre-Market Trading 12-23 08:54:24 EST
9.01
+0.04
+0.45%
盘前9.02
+0.01+0.11%
08:45 EST
High9.17
Low8.88
Vol3.20M
Open8.92
D1 Closing8.97
Amplitude3.23%
Mkt Cap700.65M
Tradable Cap446.46M
Total Shares77.76M
T/O28.88M
T/O Rate6.47%
Tradable Shares49.55M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Kura Oncology’s Promising Clinical Advances and Strategic Pipeline Developments Justify Buy Rating
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.